Citadel Advisors
PRAX icon

Citadel Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Citadel Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Sell
35,600
-14,400
-29% -$4.45M ﹤0.01% 3065
2025
Q4 		$14.7M Buy
50,000
+37,800
+310% +$7.04M ﹤0.01% 2726
2025
Q3 		$647K Buy
12,200
+1,700
+16% +$82.4K ﹤0.01% 8516
2025
Q2 		$442K Sell
10,500
-54,800
-84% -$2.09M ﹤0.01% 8931
2025
Q1 		$2.47M Buy
65,300
+22,700
+53% +$1.42M ﹤0.01% 5126
2024
Q4 		$3.28M Buy
42,600
+11,900
+39% +$861K ﹤0.01% 4692
2024
Q3 		$1.77M Buy
30,700
+18,500
+152% +$999K ﹤0.01% 5773
2024
Q2 		$505K Buy
12,200
+2,800
+30% +$132K ﹤0.01% 8024
2024
Q1 		$574K Buy
9,400
+9,334
+14,142% +$419K ﹤0.01% 8084
2023
Q4 		$1.47K Buy
+66
New +$1.19K ﹤0.01% 13820
2023
Q2 		– Sell
-180
Closed -$2.18K – 15042
2023
Q1 		$2.18K Buy
180
+167
+1,285% +$7.05K ﹤0.01% 14191
2022
Q4 		$476 Buy
+13
New +$405 ﹤0.01% 14646

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors's PRAX Position: Q1 2026 in Review

Citadel Advisors sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 34,917 shares — an estimated $10.8M sold.

Citadel Advisors first reported a position in PRAX in Q4 2020 and held it in 21 quarters. The position peaked at $87.8M in Q4 2020. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Citadel Advisors reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 34,917 Praxis Precision Medicines shares in Q1 2026, an estimated $10.8M.
  • Citadel Advisors first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 21 quarters.
  • Citadel Advisors's Praxis Precision Medicines position peaked at $87.8M in Q4 2020.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.